

# Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H2 2019

<https://marketpublishers.com/r/HC25F813EDA0EN.html>

Date: December 2019

Pages: 78

Price: US\$ 3,500.00 (Single User License)

ID: HC25F813EDA0EN

## Abstracts

Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H2 2019

### SUMMARY

According to the recently published report 'Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H2 2019'; Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) pipeline Target constitutes close to 15 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Hypoxia-inducible factor 1-alpha is a subunit of a heterodimeric transcription factor encoded by the HIF1A gene. It plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. It activates the transcription of erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor and HILPDA under hypoxia condition.

The report 'Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H2 2019' outlays comprehensive information on the Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are

being developed by Companies / Universities.

It also reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Ophthalmology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Melanoma, Breast Cancer, Colorectal Cancer, Diabetic Foot Ulcers, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Ischemia, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Peritoneal Cancer, Rectal Cancer, Small-Cell Lung Cancer, Systemic Sclerosis (Scleroderma), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Wounds.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

The report reviews Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics and enlists all their major and minor projects

The report assesses Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Overview

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Development Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Assessment Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Companies Involved in Therapeutics Development

Canton Biotechnologies Inc

Daiichi Sankyo Co Ltd

Emerald Health Sciences Inc

Ildong Pharmaceutical Co Ltd

Jiuzhitang Co Ltd

NewLink Genetics Corp

OliPass Corporation

Oncolmmune Inc

OncoSpherix Inc

Phio Pharmaceuticals Corp

Vascular Biogenics Ltd

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Drug Profiles

**A-503451A - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Antisense Oligonucleotide to Inhibit HIF1A for Melanoma - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Antisense RNAi Oligonucleotides to Inhibit HIF-1 Alpha for Oncology and Retinal Disease - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**deferoxamine - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Echinomycin - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**EHP-101 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**FS-7 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**HS-1793 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**IDF-11774 - Drug Profile**

Product Description

Mechanism Of Action

R&D Progress

KCN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLG-207 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-16388 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TR-764 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Dormant Products

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Discontinued Products

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Product Development

Milestones

Featured News & Press Releases

Aug 27, 2019: Emerald Health concludes Phase I trial of CBD-based therapeutic

Jul 02, 2019: Emerald Health Pharmaceuticals demonstrates repair of nerve damage related to multiple sclerosis

Jun 19, 2019: Emerald Health Pharmaceuticals to present Preclinical Data on EHP-101 at the 29th Annual Symposium of the International Cannabinoid Research Society

Apr 17, 2019: Emerald Health Pharmaceuticals receives U.S. Drug Enforcement

Administration determination that the active ingredient in its lead product candidate is not a controlled substance

Apr 02, 2019: NewLink Genetics presents encouraging phase 2 results for NLG207 in ovarian cancer at AACR 2019

Mar 19, 2019: Emerald Health Pharmaceuticals cannabinoid-derived drug candidate, EHP-101, shows a unique mechanism of action in systemic sclerosis model, indicating key differences compared to ajulemic acid

Feb 27, 2019: NewLink Genetics announces clinical trial abstract presentation at AACR Annual Meeting

Feb 13, 2019: Emerald Health Pharmaceuticals and Lonza announce agreement for manufacturing of novel cannabinoid-derived drug candidate

Jan 23, 2019: Emerald Health Pharmaceuticals appoints Joachim P.H. Schupp, M.D., Dr. med. as Chief Medical Officer

Sep 28, 2018: EHP starts enrolment in EHP-101 Phase I trial for MS and scleroderma

Feb 15, 2018: Emerald Health Pharmaceuticals Granted European Orphan Designation for Systemic Scleroderma

Oct 20, 2017: Emerald Health Pharmaceuticals Granted FDA Orphan Drug Designation for Systemic Scleroderma

Oct 06, 2016: Cerulean Announces Clinical Data from CRLX101 Program at the 2016 European Society for Medical Oncology Annual Meeting

Aug 18, 2016: Cerulean Announces Reduction in Force

Aug 18, 2016: Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin Combination in Relapsed Renal Cell Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Canton Biotechnologies Inc, H2 2019  
Pipeline by Daiichi Sankyo Co Ltd, H2 2019  
Pipeline by Emerald Health Sciences Inc, H2 2019  
Pipeline by Ildong Pharmaceutical Co Ltd, H2 2019  
Pipeline by Jiuzhitang Co Ltd, H2 2019  
Pipeline by NewLink Genetics Corp, H2 2019  
Pipeline by OliPass Corporation, H2 2019  
Pipeline by Oncolmmune Inc, H2 2019  
Pipeline by OncoSpherix Inc, H2 2019  
Pipeline by Phio Pharmaceuticals Corp, H2 2019  
Pipeline by Vascular Biogenics Ltd, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Dormant Products, H2 2019 (Contd..2), H2 2019  
Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Top 10 Indications, H2 2019  
Number of Products by Mechanism of Actions, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Routes of Administration, H2 2019  
Number of Products by Stage and Routes of Administration, H2 2019  
Number of Products by Molecule Types, H2 2019  
Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Canton Biotechnologies Inc  
Daiichi Sankyo Co Ltd  
Emerald Health Sciences Inc  
Ildong Pharmaceutical Co Ltd  
Jiuzhitang Co Ltd  
NewLink Genetics Corp  
OliPass Corporation  
OncoImmune Inc  
OncoSpherix Inc  
Phio Pharmaceuticals Corp  
Vascular Biogenics Ltd

## I would like to order

Product name: Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/HC25F813EDA0EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HC25F813EDA0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970